Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Retatrutide
Other

Retatrutide

Tracked across 1 events · 6 articles · First seen Aug 12, 2026 · Last active Aug 13, 2026

Sentiment
70
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
4 70
Regulatory
Lilly sues six over black-market retatrutide
Eli Lilly and Company filed six lawsuits against U.S. companies accused of illegally selling black-market versions of its experimental obesity drug retatrutide. The defendants include compounding pharmacies, medical spas, and online sellers: Aesthetic Envy Cosmetic…
Impact: Retatrutide is the experimental obesity drug at the center of the lawsuits. It remains in Phase 3 trials with positive results, and the legal actions aim to curb black-market sales, supporting its future commercial prospects.
Aug 12, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Retatrutide live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.